A recent concept paper by Babar and published in PharmacoEconomics questioned the usefulness and applicability of pharmacoeconomics for formulary development in developing countries, which stirred substantial controversy. We wish to support and build upon the contribution of Shafie and Hassali by providing our views as researchers in Thailand.Although we recognize the commentary as an exercise to open debate rather than a validated model, we wish to express our concern about its uncritical publication. The model may easily create confusion among readers due to its reductionist, misleading and static nature. In this response, we elaborate on the model's deficiencies that invalidate it from its conception and offer a constructive alternative to the assessment of the 'utility' of economic evaluation.
展开▼
